secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0001104659-25-016779
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis Pharma reports FY2024 net loss of $19.0M; follow-on offering extends cash runway into 2027
--------------------------------------------------------------------------------

- Cash and cash equivalents $18.5M as of Dec 31, 2024, down from $19.1M; net loss $19.0M, vs $22.3M in 2023.
- NXP800 Phase 1b in platinum-resistant ARID1a-mutated ovarian cancer ongoing; updated data expected Q2 2025.
- NXP900 Phase 1a dose escalation continues; Phase 1b program anticipated to begin mid-2025.
- Follow-on offering completed Feb 2025 raised $15.5M gross, extending cash runway into 2027.
- NXP800 granted Orphan Drug Designation by FDA for ARID1a-deficient ovarian, fallopian tube, and peritoneal cancers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465925016779/0001104659-25-016779-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465925016779/tm257439d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-016779

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer